- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Use of ivermectin, hydroxychloroquine, favipiravir dropped from new COVID-19 treatment guidelines
New Delhi: The Union Health Ministry on Monday dropped the use of ivermectin, hydroxychloroquine, and the anti-viral favipiravir from its COVID-19 treatment guidelines.
The nine-page guidelines have not mentioned the use of these medicines which have been used widely by doctors to treat Covid-19 patients.
Earlier guidelines given by Indian Council of Medical Research (ICMR) has mentioned the use of ivermectin in certain quantity only.
The use of medicines such as zinc, multivitamins, etc. prescribed by the doctors to asymptomatic or mildly symptomatic Covid-19 is also not mentioned except the use of Anti-Pyretic and Anti-tussive for symptomatic relief.
Guidelines for rational use of CT (HRCT)
The revised guidelines issued on May 27, also issue guidelines for the rational use of CT (HRCT) with reasons that why, when and what are those appropriate indications indication for HRCT imaging of the chest in COVID-19 patients.
Further, the Directorate General of Health's (DGH) COVID-19 guidelines stressed the importance of a monitoring sheet for Covid-19 patients at home and a six-minute simple clinical test to assess cardiopulmonary exercise tolerance.
The guidelines have stressed the use of wearing masks, physical distancing and hand hygiene.
The guidelines have mentioned the use of Remedesivir and it is advised to be used only in select moderate/severe hospitalised COVID-19 patients on supplemental oxygen within 10 days of onset of disease.
The guidelines for use of Tocilizumab which is an immunosuppressant drug was also mentioned in the guidelines. It has been approved by the Drugs Controller General of India (DCGI). It mentioned in the guidelines on what conditions the drug should be used.
Read also: Ocugen pays USD 15 million upfront to Bharat Biotech for Covaxin rights in Canada
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story